Research Specialization
T Cell Expression Platforms, CRISPR Gene Editing & Computational Biology Optimization.
T Cell Expression Platforms & Adoptive Immunotherapy
Pioneering TCR gene modification, primary cell expansion, and bioinformatic assay design for next-generation personalized cancer therapeutics.
Engineering Primary Human T Cells for Cancer Therapy
At Tmunity Therapeutics, my research centers on creating robust TCR expression platforms in primary human CD4+ and CD8+ T cells. Utilizing recombinant lentiviral vectors and targeted CRISPR/Cas9 genomic modifications, we enhance T cell specificity and longevity against solid tumors.
To maximize therapeutic efficacy, I integrate computational biology toolsets (written in Python and R) to optimize T cell expansion dynamics and analyze TCR-dextramer binding affinity. This dual wet-lab and dry-lab approach accelerates candidate selection and generates critical data supporting regulatory submissions.
Viral Vector Engineering
High-titer lentiviral vector production and optimization for primary lymphocyte transduction.
CRISPR/Cas9 Knockout
Targeted genomic editing to eliminate inhibitory pathways and enhance T cell persistence.
Dextramer Binding Analysis
Bioinformatic quantification of TCR antigen specificity using Python/R script pipelines.
Tumor Specimen Processing
Aseptic processing of patient tissue samples and tumor-infiltrating lymphocyte isolation.